Charles River Laboratories International (NYSE:CRL) Updates FY 2026 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 10.800-11.300 for the period, compared to the consensus earnings per share estimate of 11.050. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Wall Street Analyst Weigh In

Several research firms have commented on CRL. Mizuho set a $192.00 target price on Charles River Laboratories International in a report on Friday. Barclays upped their price target on Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday. Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a report on Monday, April 20th. Finally, Robert W. Baird set a $213.00 price target on Charles River Laboratories International in a report on Friday. Eleven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $205.86.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded down $3.72 during midday trading on Friday, reaching $177.96. 978,093 shares of the company’s stock traded hands, compared to its average volume of 805,437. The company has a market cap of $8.78 billion, a price-to-earnings ratio of -47.33, a P/E/G ratio of 2.20 and a beta of 1.44. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.02 and a current ratio of 1.36. Charles River Laboratories International has a one year low of $132.58 and a one year high of $228.88. The stock has a 50 day moving average of $170.79 and a 200 day moving average of $183.34.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The company had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.Charles River Laboratories International’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities research analysts anticipate that Charles River Laboratories International will post 10.97 EPS for the current fiscal year.

Trending Headlines about Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River reported Q1 EPS of $2.06, ahead of the $1.96 consensus, and revenue of $995.8 million, also above estimates. Reuters article
• Positive Sentiment: Reuters noted steady demand for drug discovery and development services, suggesting the core business is stabilizing. Reuters article
• Neutral Sentiment: Management reaffirmed full-year 2026 EPS guidance of $10.80 to $11.30, which is in line with expectations but not a major upside surprise. Earnings release and transcript
• Negative Sentiment: Investors appear concerned that margin compression and weak organic growth may offset the earnings beat, which helps explain the stock’s weakness. Zacks article
• Negative Sentiment: One recent analyst note downgraded CRL to Sell, citing a strong share rally, muted near-term growth, and longer-term risks. Seeking Alpha article

Institutional Trading of Charles River Laboratories International

A number of hedge funds have recently bought and sold shares of CRL. Jones Financial Companies Lllp increased its position in Charles River Laboratories International by 167.6% during the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after acquiring an additional 1,074 shares during the last quarter. Empowered Funds LLC purchased a new stake in Charles River Laboratories International during the first quarter valued at $418,000. American Century Companies Inc. increased its position in Charles River Laboratories International by 41.9% during the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock valued at $830,000 after acquiring an additional 1,616 shares during the last quarter. Brown Advisory Inc. increased its position in Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock valued at $354,000 after acquiring an additional 114 shares during the last quarter. Finally, California Public Employees Retirement System increased its position in Charles River Laboratories International by 3.9% during the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock valued at $12,837,000 after acquiring an additional 3,198 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.